Fewer than one in 10 patients that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the global health agency as it issues its inaugural recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for increased and just access to this class of drugs.
Per projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key hurdles to universal access to the injections that can aid individuals in losing considerable weight, says the agency.
Skinny Jab Shortage
Despite the present most optimistic scenario, the supply of such drugs could only cover about 100 million people – under 10% of those who need them, as stated by the health organization.
The guideline encourages governments and firms to expand access, by approaches including patent sharing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is set to lapse in a number of countries in 2026.
How Obesity Injections Work
The injections mimick a biological compound to reduce digestion speed, curb appetite and increase satiety so individuals eat less.
People typically start to lose weight after several weeks of beginning the weekly injections.
Evidence points to people may regain a significant portion after a year of stopping the treatment, when their usual food cravings come back.
Being above a healthy weight increases your likelihood for developing medical conditions, including diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight concerns people in all nations and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.
